Early detection of decompensated heart failure using voice analysis
The challenge
Heart Failure (HF) is one of the major life-threatening manifestations of cardiovascular diseases and one of the leading cause of deaths on a global level. It is associated with high hospital readmission rates, morbidity, and mortality.[1]
Currently, the problem of HF is being addressed through a combination of medical interventions, lifestyle modifications, and patient management strategies. However, despite these current approaches, several challenges exist in managing HF:
Disease progression: HF is a chronic and progressive condition, and managing its progression can be challenging. The underlying causes may continue to worsen over time, impacting the outcome for the patient.
Hospital readmissions: HF patients experience frequent hospital readmissions due to decompensation (recurrence of heart failure symptoms) or other complications. This can affect patient quality of life and worsen their outlook. It also puts a strain on healthcare resources and increases healthcare costs. Many of the hospitalisations could be prevented.
Limited predictive capability: The current approach lacks highly accurate and real-time predictive models to identify patients sufficiently early who are at high risk of decompensation. The ability to proactively detect worsening symptoms or impending HF exacerbations could significantly improve outcomes.[2]
Patient adherence: Adherence to medication regimens, lifestyle modifications, and self-care management can be challenging for HF patients. Non-adherence may lead to poor symptom control, disease progression, and increased hospitalisations.[3]
Resource constraints: Access to specialised healthcare professionals, diagnostic tests, and advanced interventions may be limited, increasingly even in high-income countries. This can impede optimal care for HF patients, especially in rural areas with more pronounced resource constraints.[4]
The standard of care in HF monitoring is to keep track of patient’s symptoms and weight as an impending decompensation may be evident in a substantial weight increase within a few days. However, these indicators tend to signal inappropriately and very late.[5]
The solution
Lead partner and start-up Noah Labs proposes an innovative digital medical device – Noah Labs Vox – consisting of a voice-based machine learning (ML) model to predict HF-related decompensation based on voice analysis early and accurately.
Noah Labs Vox offers significant advantages over existing devices and solutions. By utilising advanced algorithms and data analytics, the device can accurately detect signs of decompensation several days before traditional indicators become apparent. This early prediction capability is crucial for timely intervention and proactive management of HF patients.
One key advantage of the device is its non-invasive nature. Unlike existing devices that may require implants or frequent blood drawing, the speech-based ML model enables remote monitoring and analysis of voice data. This non-intrusive approach enhances patient comfort and compliance while minimising the need for invasive procedures.
By leveraging the power of ML, the device can identify unique vocal biomarkers that may go unnoticed by conventional diagnostic methods. This provides healthcare professionals with new information to monitor and assess the progression of HF, enabling early intervention and preventive measures.
In addition to its other advantages, the device has the distinct advantage of not requiring any other wearable devices for monitoring. This eliminates the potential instability and variability associated with relying on multiple devices and sensors, thereby reducing the margin of inaccuracies in the measurements and analysis.
Expected impact
As part of this EIT Health project, the consortium is conducting a multi-centre observational study to clinically validate Noah Labs’ technology, aiming to improve algorithm accuracy and accelerate the solution’s market readiness.
The project promises several potential benefits for both healthcare systems and patients. It leverages voice analysis and advanced algorithms to remotely monitor heart failure (HF) patients, reducing healthcare burden and enabling earlier detection of complications.
The voice-based ML model developed within the project provides predictive insights into HF decompensation, assisting in resource allocation by identifying high-risk patients. This remote monitoring capability is expected to enhance cost-effectiveness by decreasing hospitalisations and emergency department visits.
Overall, the approach is anticipated to lead to a significant reduction in HF-related hospitalisations, lower mortality rates, and substantial cost savings for healthcare systems.
External Partners
- Noah Labs
- IPE Institut für Politikevaluation GmbH
- German Foundation for the Chronically Ill
- DKV Servicios
- ProductLife Group
References
[1] Savarese, G. et al. (2023). Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovascular Research, 118(17), 3272-3287.
[2] Allen. L. A. et al. (2012). Decision Making in Advanced Heart Failure: A Scientific Statement From the American Heart Association. Circulation, 125, 1928–1952.
[3] Ruppar, T. M. et al. (2016). Medication Adherence Interventions Improve Heart Failure Mortality and Readmission Rates: Systematic Review and Meta-Analysis of Controlled Trials. Journal of the American Heart Association, 5 (6).
[4] Manemenn, S. M. et al. (2021). Rurality, Death, and Healthcare Utilization in Heart Failure in the Community. Journal of the American Heart Association, 10 (4).
[5] Stevenson, L. W. et al. (2023). Remote Monitoring for Heart Failure Management at Home: JACC Scientific Statement. Journal of the American College of Cardiology, 81(23), 2272-2291.
Partners
CLC/InnoStars: Spain
Partner classification: Research
Partner type: Linked/Affiliated Party
The Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) is a public research centre dedicated to biomedical research, founded in 1996 to broaden the clinical research of the Hospital Clinic de Barcelona (HCB). With >1,500 original articles and >2,500 publications annually, IDIBAPS is one of the leading biomedical research centres in Spain driving forward original multidisciplinary biomedical research on multiple diseases affecting our society, with the mission to translate “knowledge into cure”. The broad vision of IDIBAPS Strategic Plan is to improve the health and quality of life of citizens through high impact research and collaborations, at the highest level of scientific integrity, public accountability, and social responsibility. The close interaction of 100 clinical and laboratory research groups, composed by more than 460 Principal Investigators, drives forward original translational and multidisciplinary research oriented to solve relevant biological and clinical questions for human health. The researchers have access to novel and first-class infrastructures available together with six own core facilities offering a wide range of services under strict quality management controls performed at all levels. The institution has also a strong track record working in European projects (e.g. 90 projects obtained along H2020 and 36 in Horizon Europe) and has a dedicated European Projects Office (OPE) and the Knowledge and Technology Transfer Office (KTT).
Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
Carrer del Rosselló, 149, 08036 Barcelona, Spain
Key Activities in Research and Developement
1600 researchers in 100 research groups
Key Activities in Corporate Innovation
Key Innovation capacities
-Strong expertise in EIT Health projects (involved in +30 projects from all pillars since 2016)
-Internationally recognized KOLs in different fields (+100 management positions in international scientific and clinical societies)
-High volume of Clinical Trials (+200 new clinical trials performed every year) with a dedicated Clinical Trial Unit, offering an integral support
-Technology transfer (12 active spin-off; +70 active patent families)
Key Activities in Business Creation
Testing & Validation
Key Activities in Education
Medical faculties, Healthcare professional education/training
CLC/InnoStars: Spain
Partner classification: Research, Hospital / University Hospital
Partner type: Core partner
Hospital Clinic of Barcelona (HCB), founded in 1906, is a university hospital with 4,500 professionals covering most of medical and surgical specialties. It belongs to the Catalan Public Hospital Network and it is both a high-complexity tertiary hospital and a community hospital providing services to more than half million citizens. HCB is placed in Spain in a top position in the areas of research and innovation (e.g. top participant in Societal Challenge 1-Health in H2020).
Hospital Clínic de Barcelona
Carrer de Villarroel, 170, 08036 Barcelona, Spain
Key Activities in Corporate Innovation
Key Innovation capacities
-Strong expertise in EIT Health projects (involved in +30 projects from all pillars since 2016)
-Internationally recognized KOLs in different fields (+100 management positions in international scientific and clinical societies)
-High volume of Clinical Trials (+200 new clinical trials performed every year) with a dedicated Clinical Trial Unit, offering an integral support
-Technology transfer (12 active spin-off; +70 active patent families)
Key Activities in Social Innovation
Healthcare provision
Key Activities in Business Creation
Testing & Validation
Key Activities in Education
-Professionals (AulaClinic) (+500 actions and +7500 participants in 2021) http://www.aulaclinic.com/
-Patients (Patient Experience Forum - Living Lab) (20 focal groups and 75 participants in 2021) https://www.clinicbarcelona.org/uploads/media/default/0002/77/9d52d7598494a2a45a34f19a56a6c4af1af6a0ae.pdf
-Citizens (PortalCLÍNIC) (+5 million visits in 2021) https://www.clinicbarcelona.org/en/portalclinic
CLC/InnoStars: Belgium-Netherlands
Partner classification: Hospital / University Hospital
Partner type: Linked/Affiliated Party
Maastricht University Medical Center+ is known both nationally and internationally for its focus on prevention and taking an integrated approach to health care: from prevention, promotion of good health, and basic care, to top-level clinical diagnostics and treatment. Patient safety is our top priority in all of our endeavours. Maastricht UMC+ has 715 beds and approximately 7,000 employees and 4,000 students. Maastricht UMC+ is part of The Netherlands Federation of University Medical Centres.
Maastricht UMC+
Maastricht UMC+, P. Debyelaan 25, 6229 HX Maastricht, Netherlands